← Back to Search

CBCT-Guided Biopsy for Lung Disease

N/A
Recruiting
Led By Kenny Lien, MD
Research Sponsored by Northwell Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up immediately after the biopsy procedure
Awards & highlights

Study Summary

This trial is testing whether cone beam computed tomography (CBCT) is a viable alternative to the standard imaging guidance modality for percutaneous transthoracic needle biopsy (PTNB) in a community hospital setting.

Who is the study for?
This trial is for adults aged 18-90 scheduled for lung biopsy at Mather Hospital's Department of Interventional Radiology. It excludes those under 18, lacking decision-making capacity, needing general anesthesia, or high-risk patients with severe emphysema, targets near airways/central vessels, or very small nodules.Check my eligibility
What is being tested?
The study compares two imaging techniques used during lung biopsies: the standard multidetector computed tomography (MDCT) and the experimental cone beam computed tomography (CBCT). The aim is to see if CBCT reduces the risk of a collapsed lung compared to MDCT.See study design
What are the potential side effects?
Potential side effects include risks associated with percutaneous transthoracic needle biopsy such as pneumothorax (collapsed lung), bleeding, infection at the puncture site, and discomfort from the procedure.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~immediately after the biopsy procedure
This trial's timeline: 3 weeks for screening, Varies for treatment, and immediately after the biopsy procedure for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To determine the incidence of pneumothorax as a complication of CBCT and CT-guided percutaneous lung biopsy
Secondary outcome measures
To compare the amount of intravenous midazolam used between biopsy imaging guidance modality
Interventional procedure
To compare the the amount of intravenous fentanyl used between biopsy imaging guidance modality

Trial Design

2Treatment groups
Experimental Treatment
Group I: multidetector computed tomography (MDCT) for percutaneous transthoracic needle biopsyExperimental Treatment1 Intervention
Multidetector Computer Tomography for percutaneous transthoracic needle biopsy
Group II: cone beam computed tomography (CBCT) for percutaneous transthoracic needle biopsyExperimental Treatment1 Intervention
Cone beam Computed Tomography (CBCT) with Navigational software guidance for percutaneous transthoracic needle biopsy

Find a Location

Who is running the clinical trial?

Northwell HealthLead Sponsor
461 Previous Clinical Trials
471,035 Total Patients Enrolled
Kenny Lien, MDPrincipal InvestigatorInterventional Radiologist
1 Previous Clinical Trials
10 Total Patients Enrolled

Media Library

Cone Beam Computed Tomography (CBCT) Clinical Trial Eligibility Overview. Trial Name: NCT05344430 — N/A
Lung Disease Research Study Groups: multidetector computed tomography (MDCT) for percutaneous transthoracic needle biopsy, cone beam computed tomography (CBCT) for percutaneous transthoracic needle biopsy
Lung Disease Clinical Trial 2023: Cone Beam Computed Tomography (CBCT) Highlights & Side Effects. Trial Name: NCT05344430 — N/A
Cone Beam Computed Tomography (CBCT) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05344430 — N/A
~3 spots leftby Jul 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top